Remote Job Cuts in Biopharma: RTO Mandates Reshaping Workforce Strategy at EMD Serono, Exelixis
NewsData.io · United States · Aug 20, 2026
Return-to-office mandates are reshaping workforce composition in the biopharma sector, with EMD Serono giving 70 remote R&D employees an ultimatum to go hybrid or lose their jobs, and Exelixis cutting 130 positions—including 33 remote workers—while planning to reopen roles as on-site positions at its California headquarters. Recruiters at PharmaLogics note a broad industry shift toward hybrid arrangements, with candidates increasingly asking whether remote policies could change post-hire. Analysts caution that remote workers aren't categorically at higher layoff risk, as drug exclusivity losses and cost restructuring also drive cuts across all work arrangements. For staffing firms serving life sciences clients, the trend signals growing demand for on-site and hybrid placements and reduced appetite for fully remote engagements.
Get the weekly brief by email
What changed in staffing last week, every Monday morning. Free. Unsubscribe anytime.
Related stories
BioSpace's Q2 2026 job market report shows biopharma job postings on the platform climbed 15% year over year and 12% quarter over quarter, marking the…
Detroit ABC affiliate WXYZ-TV (Channel 7) has eliminated at least 30 positions through a combination of buyouts and layoffs, according to sources who…
Dole Packaged Foods will permanently close its Atwater, California processing facility and a nearby Livingston laboratory, eliminating 404 jobs in…
About 1,400 IRS IT employees displaced by DOGE-directed downsizing have been reorganized into 'ONE IRS Readiness' teams with no defined mission…